Evidence map›Paper›PMID 21315116›Full record

ArticleVaccine2011

Generation of Salmonella-specific Th1 cells requires sustained antigen stimulation.

Amanda J Griffin, Stephen J McSorley

Abstract read
In one paragraph

Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in immunology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Dual Immunization with SseB/Flagellin Provides Enhanced Protection againstJournal of immunology (Baltimore, Md. : 1950) · 2017
    Article
  12. Two NovelFrontiers in cellular and infection microbiology · 2017
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Amanda J GriffinDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Stephen J McSorley
University of Minnesota Medical Center · USUniversity of Minnesota System · US

Funding

Sustained adaptive immunity in the mucosaP01AI056172 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI PUDDINGTON, LYNN · 2003 to 2017
$22.3M
CD4 T Cell Response to SalmonellaR01AI055743 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MCSORLEY, STEPHEN J · 2004 to 2013
$3.5M
Typhoid priority antigen identification and vaccine developmentR01AI073672 · NIAID · UNIVERSITY OF MINNESOTA · PI MCSORLEY, STEPHEN J · 2008 to 2011
$1.6M
NIAID NIH HHS AI055743NIAID NIH HHS AI56172NIAID NIH HHS P01 AI056172NIAID NIH HHS R01 AI055743NIAID NIH HHS R01 AI073672
6 · The paper itself

Abstract

The administration of live attenuated Salmonella strains has proven to be an effective way to generate protective immunity against Salmonella infection in humans and mice. Studies in the mouse model have shown that protection requires Salmonella-specific Th1 cells, however the timing and stimulatory requirements for generating optimal Th1 responses have not been carefully examined. We used antibiotic interruption of vaccination with live attenuated Salmonella to examine the requirements for Salmonella-specific Th1 development and protective immunity. Optimal development of protective immunity to Salmonella infection required at least one week of exposure to the live attenuated Salmonella strain. In contrast, optimal development of Salmonella-specific Th1 cells required two weeks of in vivo colonization. Thus, sustained in vivo stimulation with a live vaccine strain is essential for the development of robust Salmonella-specific Th1 cells.

Indexed as

AnimalsAnti-Bacterial AgentsAntigens, BacterialMiceMice, Inbred C57BLSalmonellaSalmonella VaccinesTh1 CellsTime FactorsVaccinationVaccines, AttenuatedAnti-Bacterial AgentsAntigens, BacterialSalmonella VaccinesVaccines, Attenuated

Identifiers

PMID21315116
PMCPMC3051039
OpenAlexW2005388181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.